title: Deleterious GRM1 mutations in schizophrenia.
abstract: We analysed a phenotypically well-characterised sample of 450 schziophrenia patients and 605 controls for rare non-synonymous single nucleotide polymorphisms (nsSNPs) in the GRM1 gene, their functional effects and family segregation. GRM1 encodes the metabotropic glutamate receptor 1 (mGluR1), whose documented role as a modulator of neuronal signalling and synaptic plasticity makes it a plausible schizophrenia candidate. In a recent study, this gene was shown to harbour a cluster of deleterious nsSNPs within a functionally important domain of the receptor, in patients with schizophrenia and bipolar disorder. Our Sanger sequencing of the GRM1 coding regions detected equal numbers of nsSNPs in cases and controls, however the two groups differed in terms of the potential effects of the variants on receptor function: 6/6 case-specific and only 1/6 control-specific nsSNPs were predicted to be deleterious. Our in-vitro experimental follow-up of the case-specific mutants showed that 4/6 led to significantly reduced inositol phosphate production, indicating impaired function of the major mGluR1 signalling pathway; 1/6 had reduced cell membrane expression; inconclusive results were obtained in 1/6. Family segregation analysis indicated that these deleterious nsSNPs were inherited. Interestingly, four of the families were affected by multiple neuropsychiatric conditions, not limited to schizophrenia, and the mutations were detected in relatives with schizophrenia, depression and anxiety, drug and alcohol dependence, and epilepsy. Our findings suggest a possible mGluR1 contribution to diverse psychiatric conditions, supporting the modulatory role of the receptor in such conditions as proposed previously on the basis of in vitro experiments and animal studies.
authors.affiliation: Western Australian Institute for Medical Research/UWA Centre for Medical Research, University of Western Australia, Perth, Australia.
authors.forename: Mohammed Akli
authors.initials: MA
authors.lastname: Ayoub
authors.forename: Dora
authors.initials: D
authors.lastname: Angelicheva
authors.forename: David
authors.initials: D
authors.lastname: Vile
authors.forename: David
authors.initials: D
authors.lastname: Chandler
authors.forename: Bharti
authors.initials: B
authors.lastname: Morar
authors.forename: Juleen A
authors.initials: JA
authors.lastname: Cavanaugh
authors.forename: Peter M
authors.initials: PM
authors.lastname: Visscher
authors.forename: Assen
authors.initials: A
authors.lastname: Jablensky
authors.forename: Kevin D G
authors.initials: KD
authors.lastname: Pfleger
authors.forename: Luba
authors.initials: L
authors.lastname: Kalaydjieva
mesh_terms: D000818:Animals; D019556:COS Cells; D016022:Case-Control Studies; D002522:Chlorocebus aethiops; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009154:Mutation / Q000235:genetics*; D010375:Pedigree; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics*; D012559:Schizophrenia / Q000235:genetics*
chemical_list: D018094:Receptors, Metabotropic Glutamate; C104077:metabotropic glutamate receptor type 1